Laura Coates outlines the findings from a phase 3b trial of guselkumab versus placebo in patients with psoriatic arthritis and an inadequate response to TNF inhibitors.
Jeffrey Sparks and Zachary Wallace talk about the potential for COVID-19 being more severe in rheumatoid arthritis patients treated with rituximab or JAK inhibitors rather than TNF inhibitors.
The IL-23 inhibitor risankizumab is a promising treatment option for psoriatic arthritis, suggest results from the KEEPsAKE 2 trial presented at the EULAR 2021 Virtual Congress.
Findings from two real-world studies presented at the EULAR 2021 Virtual Congress suggest that JAK inhibitors and biologics are similarly effective for the treatment of inflammatory arthritis.
The addition of dapirolizumab pegol to standard therapy may warrant further investigation for the treatment of systemic lupus erythematosus, phase 2 trial results suggest.
